Column-Shipped 211At for Targeted Alpha Therapy: High Radiochemical Conversion in Organotin Astatination via Redox Activation
Abstract Astatine-211 is a rare heavy halogen radionuclide whose ability to form covalent carbon–astatine bonds confers distinctive chemical behavior, yet its broader application remains limited by tracer-level availability and complex aqueous speciation. Because production is restricted to a small number of specialized cyclotron facilities worldwide, direct on-site access is impractical for most research and clinical centers; accordingly, distribution from centralized production sites via column-based conveyance provides a practical strategy for expanding access to this promising α-emitter for targeted alpha therapy. This study demonstrates that oxidative activation of column-recovered 211At generates a reactive astatine species that enables efficient labeling of aryl-organotin precursors under mild, catalyst-free conditions. Structurally diverse substrates, including chloro-substituted arylstannanes, guanidyl-functionalized benzyl derivatives, and heteroaryl thiophenes, undergo rapid astatination with radiochemical conversions of 83–95%. This work establishes a practical and electronically tunable platform for 211At radiochemistry using column-shipped material, helping extend astatination chemistry beyond specialized cyclotron facilities.
Authors
- G. Tăbăcaru (ORCID: https://orcid.org/0000-0003-1757-3246)
- Lauren A. McIntosh (ORCID: https://orcid.org/0000-0001-6305-3079)
- Jennifer M. Pyles (ORCID: https://orcid.org/0000-0001-9049-4275)
- Jonathan D. Burns (ORCID: https://orcid.org/0000-0003-0301-9607)
- Sherry J. Yennello (ORCID: https://orcid.org/0000-0003-3963-5217)
- Shayden R. Fritz
- C. Lawrence
- Jehan S. Perera (ORCID: https://orcid.org/0009-0004-4610-3985)
Institutions
- University of Alabama at Birmingham (US)
- Texas A&M University (US)
Publication Details
- Journal
- ACS Organic & Inorganic Au
- Published
- 2026-11-02
- DOI
- https://doi.org/10.1021/acsorginorgau.6c00088
- Primary Topic
- Radiopharmaceutical Chemistry and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Nuclear Security Administration
- Nuclear Physics
- Office of Isotope R and D and Production